←Back to Expert Scholars
Translational Medicine / 转化医学HER2 Ultra-Low
Giuseppe Curigliano
MD, PhD
🏢European Institute of Oncology (IEO)🌐Italy
Head, Early Drug Development Division
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Giuseppe Curigliano leads early drug development at IEO Milan and is a global HER2 ADC trialist. He co-authored ESMO guidelines addressing HER2-low breast cancer classification. His work drives selection criteria for next-generation HER2-directed therapies.
Share:
🧪Research Fields 研究领域
Early-phase trials
ADCs
HER2 biology
Breast cancer
Biomarker selection
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Giuseppe Curigliano 的研究动态
Follow Giuseppe Curigliano's research updates
留下邮箱，当我们发布与 Giuseppe Curigliano（European Institute of Oncology (IEO)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment